Compare Enovix Corporation (ENVX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Nuwellis Inc — how do they compare? Enovix Corporation trades at $2.56 (market cap $549.72M), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Enovix Corporation is far larger — about 249.9× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 6,635,687). Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Nuwellis Inc for 26 Days on average.
| ENVX | NUWE | |
|---|---|---|
Market Cap | $549.72M | $2.20M |
Volume | 6,635,687 | 121,544 |
Sector | Industrials | Health |
52-Week High | $13.19 | $146.65 |
52-Week Low | $2.50 | $0.68 |
Typical Hold Time | 11 Days | 26 Days |
Enterprise Value | $611.42M | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% on the day, reflecting a bearish technical outlook with significant selling pressure indicated by moving averages and oscillators. Fundamentally, the company is in a high-growth, pre-profitability phase, with revenue growing to $36 million in 2026 but net losses widening to -$170 million. Recent news is dominated by a sudden CEO resignation in August 2026, though the company reaffirmed its strategy and operational guidance.
The investment case hinges on the company's advanced battery technology and expansion plans, particularly in the defense and drone sectors, against a backdrop of persistent cash burn and high execution risk. Analyst consensus remains bullish with a $10.75 price target, but the stock faces near-term volatility from leadership uncertainty and the challenging path to profitability.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
